Eisai Co., Ltd. (ESAIY)
Eisai Co., Ltd.
4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 11,067
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Haruo Naito | CEO, Representative Corporate Officer & Director | N/A | N/A | 1947 |
| Mr. Gary Hendler | Senior VP & President of EMEA Region | N/A | N/A | 1966 |
| Dr. Lynn D. Kramer FAAN, M.D. | VP & Chief Clinical Officer | N/A | N/A | 1950 |
| Ms. Yanhui Feng | Senior Vice President | N/A | N/A | 1972 |
| Mitsuru Shomon | VP & CFO | N/A | N/A | N/A |
| Mr. Keisuke Naito | Representative Corporate Officer, EVP, COO & Chief Growth Officer | N/A | N/A | 1988 |
| Makoto Hoketsu | VP & Chief Information Officer | N/A | N/A | N/A |
| Mr. Masatomi Akana | Senior VP, Chief Government Relations Officer & Chief IR Officer | N/A | N/A | 1967 |
| Shin Kato | VP, General Counsel & Chief Compliance Officer | N/A | N/A | 1971 |
| Ms. Sayoko Sasaki | Vice President of Corporate Communications & Sustainability | N/A | N/A | 1968 |
Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Corporate Governance
Eisai Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
